1.

2. Fig. 4 BMC and possible osteoclastosteoblast interactions. Cells in osteoclast (red) and osteoblast (light and dark blue) lineages are shown. (a) Recruitment of osteoclast precursors in the early initiation phase. (b) Differentiation of osteoclasts on the... Koichi Matsuo , Naoko Irie Osteoclastosteoblast communication Archives of Biochemistry and Biophysics Volume 473, Issue 2 2008 201 - 209 http://dx.doi.org/10.1016/j.abb.2008.03.027 3. 2~4 4. ? 5. 45-50 55-60 65 22% 15%Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th Edition, 1999 6. ? Kanis JA, et al. Osteoporosis Int. 1997;7:390-406 7. 8. 9. e9e94 : 1500mg 40 500 27 1500*40%*27% = 162mg 29-39 362-487 25 1500*35%*25% = 131mg 21 262 35 1500*21%*35% = 110mg 13 162 29 1500*13%*29% = 57mg 9 112 27 1500*9%*27% = 36mg 10. . , 2002 4 11. : (:,,) : RANKL : : 12. 13. : FDA , : , , , ( ) , 10-15, 14. : : ( 3~6) , 15. : , , , , : , 30() , ,() () 16. : , , : 17. 18. FDA , 24 19. 37 teriparatide 20g 65 : 637 ( 21 ) BMD Change: Lumbar Spine: +7.4% (group mean = 9.7 7.4%) Total Hip: +5.2% (group mean = 2.6 4.9%) Teriparatide Jiang UCSF 2005 Data from Jiang, J Bone Min Res 2003;18(11):1932-1941 20. EFOS- 9.7 18.3 23.5 26.6 29.9 28.4 27.2 23.5 15.2 26.7 29.2 28.5 26.3 29.8 31.5 29.9 37.7 38 34.4 33.1 33.6 29 29.1 31.8 37.3 17.1 12.9 11.9 10.3 12.8 12.1 14.8 0 10 20 30 40 50 60 70 80 90 100 Baseline (n=1482) 3 (n=1319) 6 (n=1238) 12 (n=1092) 18 (n=1031) 24 (n=852) 36 (n=749) Studyend (n=1206) Patients(%) Treatment Period (months) None Minor Moderate Severe 38